
IBA 2026
ANNUAL CONFERENCE

Converging Innovations:
AI, Next-Generation Biomedical Science, and Global Drug Development

October 18, 2026
The Inn at Villanova University
Radnor, Pennsylvania



PROGRAM BOOK

SCIENCE | PEOPLE | PARTNERSHIPS | INNOVATION | IMPACT

IBA 2026 ANNUAL CONFERENCE

CONFERENCE AGENDA

October 18, 2026

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

TIME	BALLROOM	TRACK 1 ROOM 114	TRACK 2 ROOM 119	TRACK 3 ROOM 120
8:00-8:30 AM	Registration & Welcome			
8:30-9:50 AM	Morning Keynote Speeches			
9:50-10:00 AM	Diamond Sponsor Spotlight opAlda & DIP			
10:00-10:30 AM	Group Photo & Coffee Break			
10:30 AM-12:00 PM		AI & RWE	Cardiovascular & Metabolic Diseases	Startup & BD
12:00-1:00 PM	Awards & Lunch Buffet			
1:00-2:30 PM		Oncology	Neurological Diseases	NAM & Organoid
2:30-3:00 PM	Coffee Break in Room 115 (Sponsor Exhibit, 8 AM-5 PM)			
3:00-4:30 PM		Statistics & Regulatory	CMC Challenges	Career Development
4:30-5:00 PM	Networking			
5:00-5:30 PM	Dinner Check-in			
5:30-6:30 PM	Evening Keynote Speeches			
6:30-8:30 PM	Live Music & Dinner Buffet			

IBA 2026 ANNUAL CONFERENCE

Morning Keynote Session

Ballroom • 8:30–10:00 AM

This keynote session brings together distinguished industry leaders to share perspectives on advancing innovative medicines from scientific breakthrough to patient impact. The talks will highlight strategies for accelerating genetic medicines, translating innovation toward commercialization, and enabling oral delivery of complex therapeutics.

KEYNOTE SPEAKERS



Filippos Kesisoglou, PhD

Scientific Associate Vice President, Merck & Co.

Enabling Oral Delivery of a Macrocyclic Peptide

8:35–9:00 AM




Anthony Vaganos, MBA

Vice President, GSK

Beginning with the End in Mind: Innovation for Commercialization

9:00–9:25 AM



Peter Marks, MD, PhD

Senior Vice President for Molecule Development & Head of Infectious Disease, Eli Lilly

Accelerating the Development of Genetic Medicines

9:25–9:50 AM

SESSION CHAIRS



Dongmei Wang, PhD

President, IBA
Executive Vice President,
Frontage Laboratories



Ling Yang, PhD

Board Chair, IBA
Associate Professor,
Lewis Katz School of Medicine
at Temple University

October 18, 2026 • 8:30–10:00 AM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

SESSION SPONSOR

opAlda LIFE SCIENCES

MORNING KEYNOTE SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026 | 8:30–10:00 AM

KEYNOTE SPEAKERS

Peter Marks

Dr. Peter Marks is an elected member of the National Academy of Medicine (NAM) and a distinguished physician-scientist with extensive experience in medicine, regulatory leadership, and pharmaceutical development. He earned his medical and graduate degrees from New York University and completed his clinical training at Brigham and Women's Hospital. He subsequently worked in academic medicine and pharmaceutical development before joining the FDA in 2012. From 2016 to 2025, he served as Director of the FDA's Center for Biologics Evaluation and Research (CBER). He currently serves as Senior Vice President for Molecule Development and Head of Infectious Disease at Eli Lilly and Company.

Filippos Kesisoglou

Dr. Filippos Kesisoglou is a Scientific Associate Vice President in the Pharmaceutical Sciences department at MSD in Rahway, New Jersey. He has over 20 years of experience in biopharmaceutics, formulation development, pharmacokinetics, and PBPK modeling for clinical development, drug product development, and CMC regulatory applications across modalities. He has made key contributions to several new drug applications across therapeutic areas and has authored or co-authored 95 manuscripts and book chapters and more than 100 conference presentations and posters. He has participated in several industry–academia consortia and is a member of the ICH M13 Bioequivalence Expert Working Group. He serves as an Editor of the Journal of Pharmaceutical Sciences and is a Fellow of AAPS and AIMBE.

Anthony Vaganos

Mr. Anthony Vaganos is an experienced US and global commercial leader in oncology, rare diseases, and neuroscience therapeutics. He earned his bachelor's degree from Cornell University, a master's degree in Biotechnology from the University of Pennsylvania, and an MBA from the Wharton School. He previously worked at Genentech in commercial roles across hematology-oncology, HER2 breast cancer, neuroscience, and rare diseases. His expertise spans business development, early- to late-stage development strategy and decision-making, pricing and market access, and launch marketing. He currently serves as Vice President and Global Medicine Commercialization Lead at GSK, focusing on oncology solid-tumor antibody–drug conjugates (ADCs).

SESSION CHAIRS

Dongmei Wang

Dr. Dongmei Wang is a pharmaceutical industry executive with nearly 30 years of experience in drug development, CMC, and global business leadership. She earned her PhD in Chemistry from Iowa State University and completed postdoctoral research at the University of Chicago. She began her industry career at Therics, supporting the development of 3D-printing drug delivery and bone repair products. She later served as Director at NovaDel Pharma, where her team supported multiple NDA programs, including FDA-approved sterile oral spray products. Since joining Frontage Laboratories in 2007, she has held several senior leadership positions, including EVP and Global Head of CMC Services. She currently serves as EVP, Global Sales and Marketing at Frontage Laboratories and President of the Innovative Biopharmaceutical Association (IBA).

Ling Yang

Dr. Ling Yang is Board Chair of the Innovative Biopharmaceutical Association (IBA) and Associate Professor at the Lewis Katz School of Medicine at Temple University. She earned her PhD from the Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, and completed postdoctoral training at the NIH and Mount Sinai School of Medicine. Her research focuses on RNA-based gene therapies for metabolic disorders, including metabolic-associated fatty liver disease, diabetes, and atherosclerosis. She has received several honors, including the NHLBI Director's Award and the NIH APIAO Young Investigator Award.

IBA 2026 ANNUAL CONFERENCE

Evening Keynote Session

October 18, 2026 • 5:30–6:30 PM • Ballroom

An inspiring evening keynote program bringing together distinguished leaders in biopharmaceutical innovation and neuroscience, with perspectives spanning the translation of science into medicines and the use of brain organoids to advance functional genetics discovery.

KEYNOTE SPEAKERS



Hugh Davis, PhD

President and COO
Aclaris Therapeutics

Innovation of Antibody-based Therapeutics with a Focus on Atopic Disease

5:35–6:00 PM



Guoli Ming, MD, PhD

Member, National Academy of Medicine
Professor of Neuroscience, Perelman School of Medicine
University of Pennsylvania

Brain Organoids as Tools for Functional Genetics Discovery

6:05–6:30 PM

SESSION CHAIRS



Dongmei Wang, PhD

President, IBA
Executive Vice President,
Frontage Laboratories



Ling Yang, PhD

Board Chair, IBA
Associate Professor,
Lewis Katz School of Medicine
at Temple University

October 18, 2026 • 5:30–6:30 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

Conference & Registration

EVENING KEYNOTE SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026 | 5:30–6:30 PM

KEYNOTE SPEAKERS

Hugh Davis

Dr. Hugh Davis is a biopharmaceutical executive with over 35 years of experience in biologics development, clinical pharmacology, and business development. He received his Ph.D. in Biochemistry from Villanova University. Dr. Davis held leadership positions at GlaxoSmithKline before joining Janssen R&D/Johnson & Johnson, where he served in several senior roles, including VP and Head of Biologics Development Sciences. He and his teams contributed to the development and approval of multiple biologic therapies, including Remicade®, Stelara®, Simponi®, Tremfya®, and Darzalex®. Dr. Davis later served as Chief Business Officer at Frontage Laboratories and subsequently held senior executive roles at Biosion, including COO, President of Biosion USA, and Chief Business & Development Officer. He currently serves as President and COO of Aclaris Therapeutics and as a member of its Board of Directors.

Guo-li Ming

Dr. Guo-li Ming is an elected member of the National Academy of Medicine (NAM) and a distinguished neuroscientist specializing in neurodevelopment and stem cell research. She received her MD from Tongji Medical University in China in 1994 and her PhD from the University of California, San Diego, in 2002. Following postdoctoral training at the Salk Institute, she joined Johns Hopkins University as an Assistant Professor in 2003 and became a Professor in 2011. Her research focuses on the molecular mechanisms of neurodevelopment and neurological disorders using patient-derived induced pluripotent stem cells. She has received numerous honors, including the Alfred P. Sloan Research Fellowship, the Society for Neuroscience Young Investigator Award, and the A. E. Bennett Research Award. She was elected to the National Academy of Medicine in 2019 and became an AAAS member in 2022. She currently serves as Perelman Professor of Neuroscience and Associate Director of the Institute for Regenerative Medicine at the University of Pennsylvania.

SESSION CHAIRS

Dongmei Wang

Dr. Dongmei Wang is a pharmaceutical industry executive with nearly 30 years of experience in drug development, CMC, and global business leadership. She earned her PhD in Chemistry from Iowa State University and completed postdoctoral research at the University of Chicago. She began her industry career at Therics, supporting the development of 3D-printing drug delivery and bone repair products. She later served as Director at NovaDel Pharma, where her team supported multiple NDA programs, including FDA-approved sterile oral spray products. Since joining Frontage Laboratories in 2007, she has held several senior leadership positions, including EVP and Global Head of CMC Services. She currently serves as EVP, Global Sales and Marketing at Frontage Laboratories and President of the Innovative Biopharmaceutical Association (IBA).

Ling Yang

Dr. Ling Yang is Board Chair of the Innovative Biopharmaceutical Association (IBA) and Associate Professor at the Lewis Katz School of Medicine at Temple University. She earned her PhD from the Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, and completed postdoctoral training at the NIH and Mount Sinai School of Medicine. Her research focuses on RNA-based gene therapies for metabolic disorders, including metabolic-associated fatty liver disease, diabetes, and atherosclerosis. She has received several honors, including the NHLBI Director’s Award and the NIH APIAO Young Investigator Award.

IBA 2026 ANNUAL CONFERENCE

AI & RWE Session

October 18, 2026 • 10:30 AM–12:00 PM Track 1 · Room 114

AI and real-world evidence are increasingly transforming how biomedical data are integrated, interpreted, and translated into drug development decisions. This session brings together leaders from academia and industry to explore multimodal AI integrating brain imaging, genomics, and clinical data in Alzheimer's disease; AI-assisted external control arms in oncology; and the evolution from paperless to autonomous bioanalysis. The session will conclude with an interactive panel discussion on opportunities, validation, and practical implementation of AI and RWE across the drug development lifecycle.

FEATURED SPEAKERS



Li Shen, PhD

Fellow of AIMBE, ACMI & AMIA | Professor of Informatics & Interim Director, Division of Informatics | Perelman School of Medicine, University of Pennsylvania

Multimodal AI for Drug Discovery: Integrating Brain Imaging, Genomics, & Clinical Data in Alzheimer's Disease

10:30–10:50 AM



Gerald L. "Gerry" Klein, MD

Founder & Principal, MedSurgPI, LLC | Adjunct Professor of Pharmacology | The Brody School of Medicine, East Carolina University

AI-Assisted External Control Arms in Oncology

10:50–11:10 AM



Xiaonan Tang, PhD

SVP, Frontage Laboratories

From Paperless to Autonomous Bioanalysis: Bridging Dry-Lab Speed, Wet-Lab Validation, and the Dark Lab Future

11:10–11:30 AM



Tianhao Wu, PhD

Founder & CHO, opAIda, Inc.

Panel Discussion

11:30 AM–12:00 PM



Kevin He, MBA

Director of Business Development | Deep Intelligent Pharma

Panel Discussion

11:30 AM–12:00 PM


SESSION CHAIRS



Yunyun (Jade) Zhou, PhD

Founder, AiMi Health

Adjunct Professor, Brown University



Weifeng Xu, PhD

Senior Scientific Director

Regulated Bioanalytics, Merck & Co., Inc.

October 18, 2026 • 10:30 AM–12:00 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

SESSION SPONSOR

DIP Deep Intelligent Pharma

Conference & Registration

AI & RWE SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026

SPEAKERS

Li Shen

Dr. Li Shen is Professor of Informatics and Interim Director of the Division of Informatics at the University of Pennsylvania's Perelman School of Medicine. He also serves as Associate Director for Bioinformatics at the Penn Institute for Biomedical Informatics and Co-Director of the Penn Center for AI and Data Science for Integrated Diagnostics. His research focuses on artificial intelligence, machine learning, medical imaging, multi-omics, and large language models, with applications in Alzheimer's disease and other complex disorders. He is a Fellow of AIMBE, ACMI, and AMIA and has authored over 450 peer-reviewed publications.

Gerald L. "Gerry" Klein

Dr. Gerald Klein is Principal at MedSurgPI, LLC and Adjunct Professor of Pharmacology at East Carolina University's Brody School of Medicine. A board-certified physician in Pediatrics and Allergy and Immunology, he has extensive experience in clinical development, medical affairs, pharmacovigilance, and product safety. Through MedSurgPI, he advises pharmaceutical and biotechnology organizations on clinical and medical strategy. His recent work focuses on Translational Medical Affairs, integrating preclinical research, clinical development, real-world evidence, and regulatory considerations. He also explores emerging technologies, including artificial intelligence, to improve evidence generation and healthcare decision-making.

Xiaonan Tang

Dr. Xiaonan Tang is Senior Vice President of Bioanalytical Services at Frontage Laboratories, leading its LC-MS/MS organization supporting global pharmaceutical and biotechnology clients. He has extensive expertise in bioanalytical method development, validation, regulatory compliance, and analysis of small molecules, peptides, oligonucleotides, and biomarkers. His work supports drug development from early discovery through clinical trials, with particular emphasis on FDA and ICH regulatory requirements. He has also advanced laboratory digital transformation through electronic workflows, informatics systems, and data management solutions. His interests include laboratory automation, emerging bioanalytical technologies, and AI-enabled applications in drug development.

PANELISTS & SESSION CHAIRS

Tianhao Wu

PANELIST

Dr. Tianhao Wu is Co-Founder of opAida.ai and an AI entrepreneur with over 24 years of experience developing enterprise AI solutions. Previously, he founded AYR, Inc., where he developed the Singularity AI platform, whose technology was selected by the IRS in 2023 to automate paper-filed tax returns. He has delivered over 200 machine learning applications across government and regulated industries, including projects involving the National Institute of Justice and Lockheed Martin. He holds a PhD in Machine Learning from Lehigh University and a bachelor's degree in Computer Science from Peking University and holds four granted patents.

Kevin He

PANELIST

Kevin He is Business Development Director at Deep Intelligent Pharma, an AI-powered contract research organization, where he supports U.S. market expansion. He brings nearly 20 years of global commercial experience across biotechnology, life sciences, industrial gases, and financial services. Previously, he held business development and commercial leadership roles at Thermo Fisher Scientific, WuXi AppTec, and Air Products, while also supporting international expansion for emerging companies. He earned both his undergraduate degree and MBA from Pennsylvania State University and actively serves in leadership roles within several nonprofit organizations in the Greater Philadelphia area.

Yunyun (Jade) Zhou

SESSION CHAIR

Dr. Yunyun (Jade) Zhou is Founder of AiMi Health, an AI-driven precision medicine company specializing in biomarker strategy, patient stratification, and clinical trial intelligence. A biomedical data scientist and precision oncology researcher, she has held research and faculty positions at Fox Chase Cancer Center, Children's Hospital of Philadelphia, University of Mississippi Medical Center, and UT Southwestern Medical Center. She has also taught AI for Precision Medicine and Cancer Informatics at Brown University. Her expertise spans cancer genomics, multi-omics, AI-enabled translational research, and real-world evidence. She serves as Co-Chair of Computational Biology and Bioinformatics at Regeneron ISEF.

Weifeng Xu

SESSION CHAIR

Dr. Weifeng Xu is Senior Scientific Director at Merck, specializing in regulated bioanalytics, immunogenicity, neutralizing antibody assays, biologics, and vaccines. Previously at Bristol Myers Squibb, he developed neutralizing antibody assays supporting major biologic therapies. At Merck, he established the Cell Assay Group and contributed to innovative bioanalytical strategies for drug development. He has co-led the AAPS Neutralizing Antibody Working Group, contributed to international bioanalytical initiatives, and authored scientific publications and patented technologies. He also co-edited Bioanalytic Aspects in Biological Therapeutics and received the 2025 Bioanalysis Outstanding Contribution Award (BOSCA).

IBA 2026 ANNUAL CONFERENCE

Cardiovascular & Metabolic Disease Session

October 18, 2026 • 10:30 AM–12:00 PM **Track 2 · Room 119**

This session brings together industry leaders and academic pioneers at the forefront of cardiovascular and metabolic medicine. Topics span next-generation clinical development for MASH, evolving incretin therapies, in vivo corrective gene editing, and clinical assay optimization, followed by an interactive panel on unmet clinical needs and future therapeutic directions.

FEATURED SPEAKERS



Anlong Li, MD, PhD

Executive Director
Madrigal Pharmaceuticals

MASH: The Next Chapter – From First Approvals to the Next Generation of Clinical Development

10:30-10:45 AM



Ajay Rao, MD

Professor & Chief, Adult Endocrinology, Diabetes and Metabolism, Temple University

Incretin Therapies for Cardiometabolic Disease in the Clinic – Past, Present, Future

10:45-11:00 AM



Xiao Wang, PhD

Assistant Professor
University of Pennsylvania

Therapeutic Gene Editing for Metabolic Diseases: Building a Platform for In Vivo Corrective Editing

11:00-11:15 AM



Xinyuan Li, PhD

Senior Principal Scientist
Johnson & Johnson Innovative Medicine

Impact of Serum Omission on Clinical ELISpot Assays

11:15-11:30 AM



Filippos Kesisoglou, PhD

Scientific Associate Vice President
Merck & Co.

Panel Discussion & Q&A: Unmet Clinical Needs and Future Directions


11:30 AM-12:00 PM

SESSION CHAIRS



Ling Yang, PhD

Board Chair, IBA
Associate Professor,
Lewis Katz School of Medicine
at Temple University



Xiaofeng Yang, MD, PhD, FAHA

Professor & Associate Director,
Lemole Center for Integrated Lymphatics and Vascular Research,
Lewis Katz School of Medicine
at Temple University

October 18, 2026 • 10:30 AM–12:00 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

Conference & Registration

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026

SPEAKERS

Anlong Li

Dr. Anlong Li is Executive Director of Clinical Development at Madrigal Pharmaceuticals, specializing in therapies for metabolic dysfunction-associated steatohepatitis (MASH). He has over 10 years of experience in drug development, leading early- and late-stage clinical programs and global Phase I–III studies. He completed clinical training in Internal Medicine and Cardiology and has extensive translational research experience in cardiovascular and metabolic diseases. Prior to joining Madrigal, he held clinical development leadership positions at Bristol Myers Squibb, Merck, and Hengrui Therapeutics. He also serves on the Executive Committee of the Innovative Biopharmaceutical Association (IBA).

Ajay D. Rao

Dr. Ajay D. Rao is Professor of Medicine and Section Chief of Adult Endocrinology, Diabetes and Metabolism at the Lewis Katz School of Medicine at Temple University. He is a practicing endocrinologist dedicated to advancing patient care, medical education, and academic leadership. His clinical expertise focuses on cardiovascular endocrinology and reducing diabetes-related complications. His research investigates the role of excess aldosterone in patients with diabetes, with particular interest in emerging therapies, including GLP-1 receptor agonists and SGLT inhibitors.

Xiao Wang

Dr. Xiao Wang is a Research Assistant Professor of Medicine at the University of Pennsylvania, specializing in the development of in vivo genome-editing therapies for genetic diseases. Her expertise includes base editing, prime editing, guide RNA engineering, and lipid nanoparticle (LNP) delivery. Her team has developed in vivo corrective-editing approaches for inherited metabolic disorders, including phenylketonuria (PKU). Her work on PKU gene editing has generated intellectual property licensed to Beam Therapeutics for therapeutic development. Her research bridges innovative genome-editing technologies with preclinical and clinical translation.

Xinyuan Li

Dr. Xinyuan Li is a Senior Principal Scientist at Johnson & Johnson Innovative Medicine, specializing in immunological assay development and evaluation across multiple therapeutic modalities. He earned his PhD in Pharmacology from Temple University and completed postdoctoral training at the University of Pennsylvania. In his current role, he oversees preclinical and clinical assessments of ELISpot and FluoroSpot assays for biologics, gene therapies, cell therapies, and therapeutic vaccines.

PANELISTS & SESSION CHAIRS

Filippos Kesisoglou

PANELIST

Dr. Filippos Kesisoglou is a Scientific Associate Vice President in the Pharmaceutical Sciences Department at MSD in Rahway, New Jersey. He has over 20 years of experience in biopharmaceutics, formulation development, pharmacokinetics, and PBPK modeling for clinical development, drug product development, and CMC regulatory applications across therapeutic modalities. He has made key contributions to several new drug applications and has authored or co-authored 95 manuscripts and book chapters and more than 100 conference presentations and posters. He has participated in industry–academia consortia and is a member of the ICH M13 Bioequivalence Expert Working Group. He serves as an Editor of the Journal of Pharmaceutical Sciences and is a Fellow of AAPS and AIMBE.

Ling Yang

SESSION CHAIR

Dr. Ling Yang is Board Chair of the Innovative Biopharmaceutical Association (IBA) and Associate Professor at the Lewis Katz School of Medicine at Temple University. She earned her PhD from the Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, and completed postdoctoral training at the NIH and Mount Sinai School of Medicine. Her research focuses on RNA-based gene therapies for metabolic disorders, including metabolic-associated fatty liver disease, diabetes, and atherosclerosis. She has received several honors, including the NHLBI Director’s Award and the NIH APIAO Young Investigator Award.

Xiaofeng Yang

SESSION CHAIR

Dr. Xiaofeng Yang is Professor and Associate Director of the Lemole Center for Integrated Lymphatics and Vascular Research at the Lewis Katz School of Medicine at Temple University. His NIH-funded research focuses on the molecular mechanisms of inflammation and immune regulation in cardiovascular and metabolic diseases, including atherosclerosis, endothelial activation, macrophage polarization, regulatory T cells, chronic kidney disease, and metabolically healthy obesity. He has authored nearly 300 peer-reviewed publications and received numerous honors, including the 2026 Temple University Faculty Research Award and the 2026 American Heart Association Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Council Outstanding Mentor Award.

IBA 2026 ANNUAL CONFERENCE

Startup & BD Session

October 18, 2026 • 10:30 AM–12:00 PM Track 3 · Room 120

Turning scientific innovation into successful biopharmaceutical ventures requires more than great science—it requires capital, strategic decision-making, and the ability to navigate a rapidly changing development landscape. This session brings together leaders from biotechnology, pharma, investment, and business development to discuss the evolving environment for science and research funding, the impact of AI, and quantitative approaches to evaluating early oncology assets. The session will conclude with an interactive panel discussion on building, funding, partnering, and advancing innovative biotech companies.

FEATURED SPEAKERS



Louis P. Kassa III, MPA
CEO, Pennsylvania Biotechnology Center (PABC), Baruch S. Blumberg Institute & Hepatitis B Foundation

On the State of the Union with Science, Funding, and Research: AI Impact

10:30-10:45 AM



Cong Chen, PhD
Scientific AVP, Merck

Evaluating Early Oncology Assets — A Quantitative Lens for BD Decisions

10:45-11:00 AM



Yuhang Zhao, PhD, MBA
Founder & Principal, Horton Inc.; ex-VP, Bayer

Panel Discussion

11:00 AM-12:00 PM



Anthony Vaganos, MS, MBA
VP, GSK

Panel Discussion

11:00 AM-12:00 PM



Chao Liu, PhD
Co-Founder & CEO, Stealth Drug Development Company

Panel Discussion

11:00 AM-12:00 PM



Rui Che
Senior Managing Director, KPMG

Panel Discussion


11:00 AM-12:00 PM

SESSION CHAIRS



Vivian (Mingyue) Li, PhD, MBA

Early Stage Investor, K2VC



Qing Liang, PhD

CEO, Neulink Pharmaceuticals

October 18, 2026 • 10:30 AM–12:00 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

Conference & Registration

IBA 2026 ANNUAL CONFERENCE

STARTUP & BD SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026

SPEAKERS

Louis P. Kassa III

Louis P. Kassa III is CEO of the Pennsylvania Biotechnology Center, Baruch S. Blumberg Institute, and Hepatitis B Foundation. He joined the organizations in 2014 as Executive Vice President and COO. Previously, he served as State Director and COO at VisionQuest National Ltd. Recognized on the Philadelphia Business Journal's "Power 100" list annually since 2023, he holds a bachelor's degree from Penn State and an MPA from Villanova University.

Cong Chen

Dr. Cong Chen is Associate Vice President of Early Oncology Statistics at Merck, providing strategic leadership in oncology drug development, external collaborations, and due diligence. He played a key role in the statistical development of Keytruda, contributing to its accelerated FDA approval. Elected a Fellow of the American Statistical Association in 2016, he has published over 110 peer-reviewed papers and serves in editorial and leadership roles within the biopharmaceutical statistics community.

SESSION CHAIRS

Vivian (Mingyue) Li

Dr. Vivian Li is a biopharmaceutical investment and business development professional spanning drug discovery, translational research, venture capital, and commercialization. She earned her PhD in Biomedical Sciences from Johns Hopkins University, completed postdoctoral research at the University of Pennsylvania, and subsequently earned her MBA from Johns Hopkins. After working at GSK in drug discovery and translational research, she joined K2VC as an investor. She facilitates cross-border investment, licensing, and strategic partnerships.

Qing Liang

Dr. Qing Liang is CEO of Neulink Pharmaceuticals, with over 17 years of experience in pharmaceutical development, clinical research, and FDA regulatory strategy. Previously at Fusion Pharmaceuticals and Actinium Pharmaceuticals, she led clinical development programs, supported multiple IND submissions and Phase I–III trials, and advanced innovative radiopharmaceutical therapies.

PANELISTS

Yuhang Zhao

Dr. Yuhang Zhao is Founder and Principal of Horton Inc., which invests in and advises emerging life sciences companies. She has extensive experience in pharmaceutical and medical device development, regulatory registration, and global commercialization. Previously, she led Bayer's Global Development organization in Asia, accelerating global product development through China-based capabilities. She also brings expertise in business development, fundraising, and strategic leadership, serving as a board member and advisor to multiple life sciences startups.

Anthony Vaganos

Anthony Vaganos is Vice President and Global Medicine Commercialization Lead at GSK, focusing on oncology antibody-drug conjugates. Previously at Genentech, he held commercial roles spanning hematology-oncology, HER2 breast cancer, neuroscience, and rare diseases. His expertise includes business development, product strategy, pricing, market access, and commercialization. He earned a bachelor's degree from Cornell University, a master's degree in Biotechnology from the University of Pennsylvania, and an MBA from the Wharton School.

Chao Liu

Dr. Chao Liu is Co-Founder and CEO of a stealth drug development company. He brings more than a decade of experience in FDA regulatory science, model-informed drug development, biopharmaceutical portfolio strategy, AI-enabled decision-making, and global operations. He earned his BS in Biological Science from Nankai University, followed by an MS in Statistics and a PhD in Immunology from the University of Florida.

Rui Che

Rui Che is a Senior Managing Director in KPMG's U.S. Economic and Valuation Services practice and leads transfer pricing for the U.S. Life Sciences sector. She has over 18 years of experience advising multinational companies, particularly in pharmaceuticals, biotechnology, and medical devices. Her expertise includes global restructuring, intellectual property structuring, transfer pricing, and tax-efficient supply chains. She also advises biotechnology startups and growing life sciences companies on global value-chain strategies.

IBA 2026 ANNUAL CONFERENCE

Oncology Innovation Session

From Right Target to Right Patient — Ultimately, Right Market

October 18, 2026 • 1:00–2:30 PM Track 1 · Room 114

Oncology innovation increasingly depends on connecting the full development journey—from selecting the right target and therapeutic modality to optimizing exposure, identifying the right patients, and ultimately reaching the right market. This session brings together experts across discovery, translational science, ADME/PK/PD, statistics, clinical development, and commercialization to explore how great science can be translated into medicines that benefit patients.

FEATURED SPEAKERS



Raymond Evers, PhD

Senior Director, J&J

Transporters and Emerging Therapeutic Modalities

1:00–1:15 PM



Shouye Wang, PhD

Senior Director, WuXi XDC

Developing Next-Generation ADCs to Overcome Drug Resistance in Cancer

1:15–1:30 PM



Chao Han, PhD

Senior Consultant
PharmTracks Consulting LLC

Engineering Right Molecule for Right Target and Testing Pharmacology in Clinical Trials

1:30–1:45 PM



Huaxin Gao, PhD

Senior Director, BeOne Medicines

Panel Discussion

1:45–2:30 PM



Cong Chen, PhD

AVP, Merck

Panel Discussion

1:45–2:30 PM




Anthony Vaganos, MBA

Vice President, GSK

Panel Discussion

1:45–2:30 PM

SESSION CHAIRS



Bonnie Wu, PhD

Associate Director, J&J



Daniel (Yue) Zhu,

MD, PhD
Senior Director, BioNTech



Yi Zhu, MD, MBA

VP, Global Clinical Development
Ionova Life Science
IBA President-Elect

October 18, 2026 • 1:00–2:30 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

Conference & Registration

ONCOLOGY INNOVATION SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCTOBER 18, 2026 1:00-2:30 PM | TRACK 1 | ROOM 114

SPEAKERS

Raymond Evers

Dr. Raymond Evers is Senior Director of Preclinical Sciences & Translational Safety at Johnson & Johnson, leading the Global Translational ADME team. He earned his PhD in Molecular Biology from the University of Amsterdam and completed postdoctoral research in Germany and the Netherlands. Previously at Merck, he established a Transporter & In Vitro Technologies group before joining J&J; in 2020. His research focuses on drug transporters, drug metabolism, and translational models for innovative therapeutics. He has authored approximately 100 publications and received the 2019 ISSX Distinguished Accomplishments Award.

Shouye Wang

Dr. Shouye Wang is Senior Director of North America Business Enablement at WuXi XDC. He previously spent nearly seven years leading CMC programs at WuXi Biologics, supporting global IND and BLA submissions for biologics, including monoclonal antibodies, bispecific antibodies, and ADCs. Earlier, he worked at Bristol Myers Squibb and Emergent BioSolutions in analytical development. He earned his PhD in Protein Chemistry from the University of Science and Technology of China and completed postdoctoral research in Sweden and the United States. He is also Founding President of the Chinese Antibody Society.

Chao Han

Dr. Chao Han is Senior Consultant at PharmTracks Consulting LLC, specializing in early drug development and clinical PK/PD strategies. With over 25 years of experience, he previously served as Senior Vice President of Early Development at Tavotek Biotherapeutics and held leadership positions at Janssen and GSK in clinical pharmacology, biologics development, and DMPK. He earned his PhD in Pharmacology and Therapeutics from the University of Manitoba and completed postdoctoral training at UCSF. He has published over 50 peer-reviewed papers and served in leadership roles within the American Society for Clinical Pharmacology and Therapeutics.

SESSION CHAIR

Bonnie Wu

Dr. Bonnie Wu is Associate Director of Biologics Discovery and Development Sciences at Johnson & Johnson Innovative Medicine. She earned her PhD in Biochemistry from the University of Rochester and completed postdoctoral research in gene therapy before entering the biotechnology industry. Since joining J&J; in 2007, she has focused on immunogenicity assessment for biologic therapeutics. She served on the USP Immunogenicity Testing Expert Panel from 2010 to 2015 and has chaired scientific programs at AAPS PharmSci 360 and PEGS Boston. She also serves as a reviewer for peer-reviewed scientific journals.

PANELISTS

Huaxin Gao

Dr. Huaxin Gao is Senior Director and Global Clinical Development Lead at BeOne Medicines (formerly BeiGene). She previously held positions of increasing responsibility at GSK, CSL Behring, and Oncolys BioPharm. She has extensive experience in oncology drug development, spanning preclinical candidate selection, first-in-human studies, IND submissions, and global Phase I-III clinical trials. Her expertise includes global clinical development strategy, translational medicine, regulatory interactions, and multinational clinical trial management. She is dedicated to accelerating innovative therapies through scientific leadership and cross-functional collaboration.

Cong Chen

Dr. Cong Chen is Associate Vice President of Early Oncology Statistics at Merck, providing strategic leadership in oncology drug development, external collaborations, and due diligence. He played a key role in the statistical development of Keytruda, contributing to its accelerated FDA approval. Elected a Fellow of the American Statistical Association in 2016, he is recognized for his expertise in innovative clinical trial design and statistical decision-making. He has published over 110 peer-reviewed papers and serves in editorial and leadership roles within the biopharmaceutical statistics community.

Anthony Vaganos

Mr. Anthony Vaganos is an experienced US and global commercial leader in oncology, rare diseases, and neuroscience therapeutics. He earned his bachelor's degree from Cornell University, a master's degree in Biotechnology from the University of Pennsylvania, and an MBA from the Wharton School. He previously worked at Genentech in commercial roles across hematology-oncology, HER2 breast cancer, neuroscience, and rare diseases. His expertise spans business development, early- to late-stage development strategy and decision-making, pricing and market access, and launch marketing. He currently serves as Vice President and Global Medicine Commercialization Lead at GSK, focusing on oncology solid-tumor antibody-drug conjugates (ADCs).

SESSION CHAIRS

Daniel (Yue) Zhu

Dr. Daniel Zhu is a Senior Director at BioNTech with nearly 20 years of experience in global clinical development and drug safety. He previously held leadership positions at AstraZeneca, CSL Behring, and Bristol Myers Squibb, overseeing IND submissions, Phase I-III clinical trials, and NDA filings. His expertise spans oncology, hematology, rare diseases, and innovative therapies, including CAR-T, bispecific antibodies, and ADCs. At BioNTech, he focuses on clinical development of bispecific antibodies. He also actively promotes global collaboration in biopharmaceutical innovation and development.

Yi Zhu

Dr. Yi Zhu is Vice President and Head of Clinical Development at Ionova Life Science and President-Elect of IBA. With nearly 30 years of experience in the U.S., she has held positions at the University of Pennsylvania, Thomas Jefferson University, the American College of Radiology, and Sanofi. Her expertise spans clinical development, translational medicine, imaging biomarkers, radiopharmaceuticals, and innovative therapeutics. She has led global IND and NDA programs through FDA approval and co-founded a medical imaging CRO, establishing strategic partnerships with leading pharmaceutical companies.


IBA 2026 ANNUAL CONFERENCE

Neurological Diseases Session

October 18, 2026 • 1:00–2:30 PM | Track 2 · Room 119

Neurological diseases, including neurodegenerative disorders and brain cancers, represent some of the most devastating and difficult-to-treat human diseases. Their profound impact on cognition, behavior, and survival, together with their increasing prevalence as the population ages, places an enormous burden on patients, families, and society. Despite major advances in neuroscience and medicine, effective treatments remain limited. The extraordinary complexity of the nervous system, the irreversible loss of neurons, and the highly invasive and heterogeneous nature of brain tumors all present formidable challenges to successful treatment. This session will highlight emerging discoveries and innovative therapeutic strategies aimed at overcoming these barriers and transforming the treatment of neurological diseases.

FEATURED SPEAKERS & PANELISTS




Yi Fan, MD, PhD

Richard H. Chamberlain Professor

Radiation Oncology · University of Pennsylvania

Next-Generation Immunomodulatory Therapeutics in CNS Tumors

1:00–1:20 PM



Hong Xu, PhD

Research Assistant Professor

University of Pennsylvania

Spread of Tau Pathology in Neurodegenerative Disease

1:20–1:40 PM



Jingwen Tan, PhD

Director, Biomarker Services

Frontage Laboratories, Inc.

Blood-Based Neuro Biomarkers: From Ultrasensitive Detection to Clinical Translation

1:40–2:00 PM



Xiaolu Yang, PhD

Professor, Cancer Biology

University of Pennsylvania

Panel Discussion

2:00–2:30 PM



Yuhong (Alice) Dong MD, PhD

Founder & Chief Scientific Officer

SunRegen Healthcare AG

Panel Discussion

2:00–2:30 PM

SESSION CHAIRS



Xiaolu Yang, PhD

Professor, Department of Cancer Biology

University of Pennsylvania



Qing Liang, PhD

CEO

Neulink Pharmaceuticals

October 18, 2026 • 1:00–2:30 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

SESSION SPONSOR

FRONTAGE

Conference & Registration

NEUROLOGICAL DISEASES SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026 | 1:00–2:30 PM | ROOM 119

SPEAKERS

Yi Fan, MD, PhD

SPEAKER • Richard H. Chamberlain Professor, University of Pennsylvania

Yi Fan is the Richard H. Chamberlain Professor in the Department of Radiation Oncology at the University of Pennsylvania. His research focuses on tissue vascularity and immunity in cancer and cardiovascular diseases, with an emphasis on understanding disease biology and developing new therapeutic approaches.

Hong Xu, PhD

SPEAKER • Research Assistant Professor, University of Pennsylvania

Hong Xu studies the molecular mechanisms of tau misfolding, pathology propagation, and neurodegenerative disease. Trained at the Technical University of Munich and Penn's Center for Neurodegenerative Disease Research, Xu has investigated therapeutic strategies and tau pathogenesis using disease models and human brain resources.

Jingwen Tan, PhD

SPEAKER • Director of Biomarker Services, Frontage Laboratories

Jingwen Tan has more than 10 years of experience in biomarker science, bioanalytical assay development, and translational research. She earned her PhD in Chemical Engineering at the University of Missouri–Columbia and completed postdoctoral training at the University of Pennsylvania. Her work centers on ultrasensitive biomarker platforms, fit-for-purpose assay validation, and clinical strategies for neurological, immune, and inflammatory biomarkers.

PANELIST & SESSION CHAIRS

Yuhong Dong, MD, PhD

PANELIST • Founder & Chief Scientific Officer, SunRegen Healthcare AG

Yuhong Dong brings more than 25 years of experience in pharmaceutical R&D; and clinical medicine. She earned her PhD at Peking University and MD at Beijing Medical University, and held clinical and medical roles at Novartis in China and Switzerland. Since founding SunRegen Healthcare AG in 2017, she has led development of SBC003, an oral therapeutic candidate designed to protect and rescue neurons in neurodegenerative diseases.

Xiaolu Yang, PhD

SESSION CHAIR & PANELIST • Professor, University of Pennsylvania

Xiaolu Yang is a Professor in the Department of Cancer Biology and an investigator at the Abramson Family Cancer Research Institute at the University of Pennsylvania. His research investigates the molecular mechanisms of cancer and neurodegenerative diseases, including cellular pathways that may reveal new therapeutic opportunities. His expertise connects fundamental biology with important questions in human disease and brings a valuable perspective to this session.

Qing Liang, PhD

SESSION CHAIR • CEO, Neulink Pharmaceuticals

Qing Liang has over 17 years of pharmaceutical industry experience spanning clinical practice, radiopharmaceutical development, medical physics, radiation dosimetry, and FDA regulatory strategy. At Fusion Pharmaceuticals and Actinium Pharmaceuticals, she led early- through late-stage clinical development programs, contributed to multiple IND submissions and Phase I–III clinical trials, and advanced innovative dosimetry-guided therapeutic strategies.

IBA 2026 ANNUAL CONFERENCE

Advancing NAMs & Organoids

October 18, 2026 • 1:00–2:30 PM Track 3 · Room 120

Organoid technologies and New Approach Methodologies (NAMs) are transforming biomedical research and drug development. This session brings together experts from academia and industry to highlight advances in cardiac and brain organoids, patient-derived tumor models, preclinical research platforms, and emerging NAMs.

FEATURED SPEAKERS




Bin Jiang, PhD

Research Director
Eureka Biotech Inc.

Label-Free Optical Mapping for Spiral Wave Visualization in 3D Cardiac Organoids

1:00–1:15 PM




Ranjie Xu, PhD

Assistant Professor
Purdue University

Vascularized neuroimmune organoids for Alzheimer's modeling and drug discovery

1:15–1:30 PM



Xin Wang, PhD

Postdoctoral Fellow
Perelman School of Medicine
University of Pennsylvania

A Standardized Patient-derived Glioblastoma Organoid Platform for Evaluating Radiotherapy Efficacy and Overcoming Resistance

1:30–1:45 PM



Tingting Zhou, PhD

Founder & CEO
HepaBio

Organoid Platform for Preclinical Research

1:45–2:00 PM



Yongzhong Zhao, MD, PhD

Senior Principal Scientist
Frontage Laboratories, Inc.

Future Direction and Current Development of NAMs and Organoid Research

2:00–2:15 PM

SESSION CHAIRS



Jian Huang, MD, PhD

Professor & Interim Chief Scientific Officer
Coriel Institute for Medical Research



Jin Liu, PhD, PMP

Founder & CEO, GenCell LLC

October 18, 2026 • 1:00–2:30 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

IBA 2026 ANNUAL CONFERENCE

ADVANCING NAMs & ORGANOIDS

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCTOBER 18, 2026 1:00–2:30 PM | TRACK 3 | ROOM 120

SPEAKERS

Bin Jiang

Dr. Bin Jiang is Research Director at Eureka Biotech Inc. He earned his PhD from the University of Macau and has conducted biomedical research in China and the United States. His expertise spans stem cells, tissue engineering, induced pluripotent stem cells (iPSCs), organoids, and bioengineering. His current research focuses on iPSC-derived cardiomyocytes, 3D cardiac organoids, and integrated platforms for cardiac electrophysiology analysis. These technologies support drug screening, cardiotoxicity assessment, and disease modeling, advancing innovative in vitro tools for drug discovery and cardiovascular research.

Ranjie Xu

Dr. Ranjie Xu is Assistant Professor at Purdue University, specializing in human pluripotent stem cell (hPSC)-based models of neurological diseases, particularly Alzheimer's disease. His laboratory develops advanced research platforms, including 2D neural cultures, 3D brain organoids, and human neuron–microglia chimeric mouse models, to investigate disease mechanisms and discover new therapies. His team also explores hPSC-based cell therapies for neurological disorders. His research has been published in Cell Stem Cell, Molecular Psychiatry, and Nature Communications, with support from the NIH and other research organizations.

Xin Wang

Dr. Xin Wang is a Postdoctoral Researcher in the Department of Neuroscience at the University of Pennsylvania's Perelman School of Medicine. Her research focuses on glioblastoma (GBM) heterogeneity, patient-derived glioblastoma organoids, and interactions between tumors and neurons. She has advanced organoid-based models for personalized treatment evaluation, including CAR-T therapy, radiation, and drug screening. By integrating tumor organoids, single-cell genomics, and advanced neural tracing technologies, she investigates GBM biology and treatment responses to support the development of innovative therapeutic strategies.

Tingting Zhou

Tingting Zhou is Founder and CEO of HepaBio, established in 2022 to advance organoid and organ-on-chip technologies for preclinical research. She studied at China Pharmaceutical University and Karolinska Institutet in Sweden and has over a decade of experience in biopharmaceutical incubation and investment. She serves on the Organoid & Organ-on-Chip and Cosmetics Toxicology Committees of the Chinese Society of Toxicology. Under her leadership, HepaBio has secured two patents, participated in a major national research program, and provided services to more than 70 biopharmaceutical companies.

SPEAKER

Yongzhong Zhao

Dr. Yongzhong Zhao is Senior Principal Scientist at Frontage Laboratories, with extensive experience in regulated bioanalysis supporting all stages of drug development under GLP, GCP, and GMP standards. His expertise includes ligand-binding and cell-based assays for PK/PD, biomarkers, immunogenicity (ADA), and neutralizing antibodies (NAbs). He is actively developing multi-omics algorithms and agentic AI approaches for regulated bioanalysis. His current work also focuses on New Approach Methodologies (NAMs), organoid-based disease modeling, and drug potency evaluation to advance innovative drug development.

SESSION CHAIRS

Jian Huang

Dr. Jian Huang is Professor and Interim Chief Scientific Officer at the Coriell Institute for Medical Research. His research focuses on understanding therapeutic resistance in cancer and translating scientific discoveries into new treatment strategies. His laboratory integrates genetic screening, molecular and cellular biology, and preclinical models to identify therapeutic targets in acute myeloid leukemia (AML) and other cancers. His current work investigates resistance to FLT3 inhibitors and venetoclax, RAS signaling, nucleotide metabolism, and synthetic lethal approaches to overcoming cancer drug resistance.

Jin Liu

Dr. Jin Liu is Founder and CEO of GenCell LLC, developing next-generation AAV-mediated in vivo immune engineering platforms for solid tumors. With over 20 years of biotechnology experience, she has advanced AAV gene therapies, CAR-T, NK cell therapies, stem cell, and exosome programs from early research through GMP manufacturing, IND submissions, and clinical translation. Previously, she served as Director of QC-GLP and MSAT in Dr. James Wilson's gene therapy program at the University of Pennsylvania. Her expertise spans CMC strategy, process development, GMP operations, quality systems, and technology transfer.

IBA 2026 ANNUAL CONFERENCE

From Evidence to Decisions: The Evolving Role of Statistics in Drug Development

October 18, 2026 • 3:00–4:30 PM **Track 1 · Room 114**

Statistics in drug development has evolved far beyond trial design and data analysis. This session explores how statistical evidence can support decision-making across clinical development, oncology dose optimization, trusted AI, and licensing. Three short talks will be followed by a panel discussion on how teams evaluate uncertainty, identify critical risks, and turn emerging evidence into decision-ready insights.

FEATURED SPEAKERS



Fei Chen, PhD

Senior Director of Biostatistics, Johnson & Johnson Innovative Medicine

Efficiency+: Expanding the Role of Statistics Beyond Trial Design and Analysis

3:00–3:15 PM



Jason Liao, PhD

Associate Vice President, Incyte Corporation

Misconceptions and Pitfalls in Oncology Dose Optimization

3:15–3:30 PM



Jian Chen, MBA, MS

Founder, President & CEO
EDETEK

From Digital Protocols to Statistical Decision-Making: A Neuro-Symbolic Strategy for Trusted AI in Regulated Clinical Development

3:30–3:45 PM



Steven Sun, PhD

Therapeutic Area Head of Statistical Decision Sciences – Cardiopulmonary, Johnson & Johnson Innovative Medicine

Panel Discussion .

3:45–4:30 PM



Ming Zhou, PhD

Senior Director of Biostatistics, Bristol Myers Squibb

Panel Discussion .

3:45–4:30 PM

SESSION CHAIRS



Qi Xia, PhD

Director, Geron
Adjunct Professor,
Loyola University Maryland



Yanfei Gao

Founder & CEO
SKY Pharmaceutical Development

October 18, 2026 • 3:00–4:30 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

SESSION SPONSOR

EDETEK LIFE SCIENCE

STATISTICS IN DRUG DEVELOPMENT

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026 | 3:00–4:30 PM

SPEAKERS

Fei Chen

Dr. Fei Chen is Senior Director of Biostatistics in Quantitative Sciences and Clinical Pharmacology, Global Development, at Johnson & Johnson Innovative Medicine. He is recognized for his leadership in clinical development, quantitative decision science, and AI-enabled drug development. His expertise spans clinical trial design, operational analytics, simulation-based decision support, machine learning, and digital twin methodologies. He leads initiatives to improve clinical development efficiency through innovative platforms for trial feasibility, project management, and clinical supply chain optimization. His work also advances forecasting, biomarker and disease progression modeling, and the responsible integration of AI into scientific workflows. An active collaborator across industry and academia, Dr. Chen is a frequent speaker and mentor dedicated to advancing statistical innovation in pharmaceutical research and development.

Jason J.Z. Liao

Dr. Jason J.Z. Liao is Interim Head of Biometrics and Associate Vice President of Biostatistics at Incyte Corporation, overseeing statistical strategy and execution across drug development programs. He earned his PhD in Statistics from the University of Michigan and has over 20 years of pharmaceutical industry experience spanning small-molecule drugs, biologics, vaccines, and biosimilars. His expertise includes end-to-end drug development strategy, innovative statistical methodologies, and efficient clinical study designs. He is actively engaged in developing fit-for-purpose statistical approaches to address complex challenges in pharmaceutical research and development. Dr. Liao is an elected Fellow of the American Statistical Association (ASA).

Jian Chen

Jian Chen is Founder, President, and CEO of EDETEK, a New Jersey-based clinical technology company specializing in data integration, biostatistics, and clinical development operations. Under his leadership, EDETEK has supported more than 3,000 clinical trials and over 50 successful regulatory submissions across oncology, autoimmune diseases, vaccines, and central nervous system disorders. His team contributed to the accelerated development of the Pfizer and Moderna COVID-19 vaccines and has extensive experience with innovative therapeutic modalities, including immunotherapies, antibody–drug conjugates, and cell and gene therapies. He is dedicated to integrating biotechnology, information technology, and genomics to improve clinical trial efficiency, regulatory readiness, and the advancement of personalized medicine.

PANELISTS & SESSION CHAIRS

PANELISTS

Steven Sun

Dr. Steven Sun is Therapeutic Area Head of Statistical Decision Sciences – Cardiopulmonary at Johnson & Johnson Innovative Medicine, with over 25 years of pharmaceutical industry experience across oncology, hematology, cardiovascular diseases, and pulmonary hypertension. He has led statistical strategies for numerous drug development programs, contributing to major global regulatory submissions. His expertise includes innovative statistical methodologies for complex clinical trial designs, safety evaluations, and real-world evidence integration. A dedicated mentor and cross-functional collaborator, he promotes rigorous quantitative approaches to support drug development decisions. His current interests focus on leveraging artificial intelligence and advanced analytics to enhance data-driven decision-making in clinical development.

Ming Zhou

Dr. Ming Zhou is Senior Director of Biostatistics at Bristol Myers Squibb, specializing in statistical support for cell therapy development programs. He earned his PhD in Statistics from Iowa State University and has over 15 years of pharmaceutical research and development experience across oncology, immunology, diabetes, and cell therapy. His expertise spans clinical trial design, regulatory submissions, and quantitative decision-making throughout the drug development lifecycle. He is dedicated to applying innovative statistical methodologies and rigorous quantitative approaches to accelerate the development of new therapies.

SESSION CHAIRS

Qi Xia

Dr. Qi Xia is a biostatistician with extensive experience leading statistical strategy for oncology programs across solid tumors and hematologic malignancies. She holds a PhD in Statistics from Temple University and an MS in Financial Engineering from the University of Southern California. Her expertise spans Phase I–III clinical trial design, regulatory submissions, real-world evidence, Medical Affairs, and postmarketing research. Previously, she led statistical work on oncology programs at Johnson & Johnson and evaluated external oncology assets for licensing due diligence. She currently serves as Director at Geron and lead statistician for its myelodysplastic syndromes (MDS) programs. She is also an Adjunct Professor at Loyola University Maryland and Managing Director of the Journal of Biopharmaceutical Statistics.

Yanfei Gao

Yanfei Gao is Founder and CEO of SKY Pharmaceutical Development, a contract research organization (CRO) specializing in statistical services and functional service provider (FSP) staffing. She has over 17 years of combined industry and academic experience in drug development and regulatory affairs across the United States, China, and Canada. Previously, she held statistician and lead statistician positions at Merck KGaA, Roche, The Hospital for Sick Children (SickKids), and Biohaven's China subsidiary. She earned her degrees in Statistics and Computer Science from McMaster University in Canada.

IBA 2026 ANNUAL CONFERENCE

CMC Challenges Session

October 18, 2026 • 3:00-4:30 PM | Track 2 · Room 119

CMC development is where scientific innovation must be translated into a robust, scalable, and regulatory-ready product. This session brings together experienced CMC leaders to explore critical challenges across drug substance, drug product, analytical development, and regulatory strategy—from the art of drug substance development and evolving extractables and leachables requirements to leveraging 505(b)(2) precedents to inform development decisions. The session will conclude with an interactive panel discussion on practical CMC challenges and strategies across the drug development lifecycle.

FEATURED SPEAKERS



Hui-Yin (Harry) Li, Ph.D.

Founder & CEO, Wilmington PharmaTech

The Art of Drug Substance Development

3:00-3:20 PM



Madhu Pudipeddi, Ph.D.

Senior Vice President, Technical Operations | Prelude Therapeutics

Unlocking 505(b)(2) Precedents: A Purpose-Built Tool for Curated Drug Monographs

3:20-3:40 PM



Kevin Li, Ph.D.

Senior Director of CMC Analytical | Frontage Laboratories Inc.

Navigating Extractables and Leachables: Meeting Today's Standards

3:40-4:00 PM



Hong Lin, Ph.D.

Senior Vice President, Drug Discovery | Quanta Therapeutics

Panel Discussion

4:00-4:30 PM



Xiaodan Ji, Ph.D.

Senior Principal Scientist GSK

Panel Discussion

4:00-4:30 PM

SESSION CHAIRS



Huan Cai, Ph.D.

CMC Program Lead, Syncromune



Selina Chen, Ph.D., MBA

Analytical CMC & QC Professional | National Resilience



Dongmei Wang, Ph.D.

Executive Vice President, Frontage Laboratories, Inc. | President, IBA

October 18, 2026 • 3:00-4:30 PM

The Inn at Villanova University

601 County Line Road, Radnor, PA 19087

www.iba-usa.org

SESSION SPONSOR

WILMINGTON PHARMATECH

Conference & Registration

CMC CHALLENGES SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026 | 3:00–4:30 PM

SPEAKERS & PANELISTS

Harry Li

Dr. Harry Li is Founder, President and CEO of Wilmington PharmaTech, established in 2003. He has over 30 years of experience in drug discovery and development, specializing in API process development, cGMP manufacturing, solid-state chemistry, and intellectual property. He earned his PhD in Organic Chemistry from the Tokyo Institute of Technology and previously held R&D; positions at DuPont, DuPont Merck, and Bristol Myers Squibb. He has authored more than 100 patents and scientific publications, including key patents supporting several blockbuster drugs.

Madhu Pudipeddi

Dr. Madhu Pudipeddi is Senior Vice President of Technical Operations at Prelude Therapeutics, overseeing drug product development, manufacturing, and clinical supply operations. He previously spent more than 16 years at Novartis Pharmaceuticals in drug development and technical operations leadership, contributing to the development and commercialization of several new molecular entities. Earlier, he worked at Bristol Myers Squibb in drug discovery and development. He earned his PhD in Pharmaceutical Sciences from the University of Wisconsin–Madison and his BS in Pharmaceutical Sciences from Andhra University, India.

Kevin Li

Dr. Kevin Li is Senior Director of CMC Analytical Services at Frontage Laboratories, with 17 years of experience in analytical development. His expertise includes analytical method development and validation, extractables and leachables, nitrosamine analysis, and impurity identification. Previously, he worked at Abon Pharmaceuticals in complex generic drug development and supported early-stage drug discovery programs. He earned his PhD in Organic Chemistry from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and completed postdoctoral research at Roswell Park Cancer Institute. He has contributed to 28 scientific publications and one patent.

Hong Lin

Dr. Hong Lin is Senior Vice President of Drug Discovery at Quanta Therapeutics. She earned her PhD in Organic Chemistry from Brandeis University and completed postdoctoral training as an NIH Fellow at Memorial Sloan Kettering Cancer Center. She began her industry career at GlaxoSmithKline, working across oncology, neuroscience, and regenerative medicine, and later served as Head of Early Discovery at Prelude Therapeutics. Outside of work, she enjoys Chinese painting and indigenous art, bringing the same creativity and imagination to scientific discovery.

PANELIST & SESSION CHAIRS

Xiaodan Ji

Dr. Xiaodan Ji is a Senior Principal Scientist at GSK with 10 years of experience in biologics development, bioprocessing, analytical sciences, and technology transfer. She leads cross-functional collaborations supporting complex development programs, with expertise in process understanding, analytical method implementation, and technology transfer. She earned her PhD in Molecular and Cell Biology from the Chinese Academy of Sciences and completed postdoctoral training at the University of California, Berkeley, and the University of Pennsylvania. She has authored more than 10 peer-reviewed scientific publications.

Huan Cai

Dr. Huan Cai is CMC Project Lead at Syncromune, with nearly a decade of biopharmaceutical industry experience in early- and late-stage biologics development. Her expertise spans analytical, formulation, and process development, regulatory strategy, and CRO/CDMO management. She previously held positions at Teva Pharmaceuticals, Frontage Laboratories, and the University of Texas. Dr. Cai earned her PhD in Biology from the Chinese Academy of Sciences and completed postdoctoral training at the National Institutes of Health (NIH).

Selina Chen

Dr. Selina Chen is an experienced CMC, analytical development, and quality control professional specializing in cell and gene therapy products. She earned her PhD in Molecular Biology from the University of Science and Technology of China and an MBA from Villanova University. She has held R&D;, Analytical CMC, and QC positions across multiple CDMO organizations. Her expertise includes analytical method development and validation, product characterization, technology transfer, stability studies, and IND/BLA submission support. She brings extensive cross-functional experience collaborating with development, manufacturing, quality, and regulatory teams.

Dongmei Wang

Dr. Dongmei Wang is a pharmaceutical industry executive with nearly 30 years of experience in drug development, CMC, and global business leadership. She earned her PhD in Chemistry from Iowa State University and completed postdoctoral research at the University of Chicago. Previously, she served as Director at NovaDel Pharma, supporting multiple NDA programs, including FDA-approved products. Since joining Frontage Laboratories in 2007, she has held several senior leadership positions, including Global Head of CMC Services. She currently serves as Executive Vice President at Frontage Laboratories and President of the Innovative Biopharmaceutical Association (IBA).

IBA 2026 ANNUAL CONFERENCE

Career Development Session

Empowering the Next Generation of Biopharma Leaders

October 18, 2026 • 3:00–4:30 PM **Track 3 · Room 120**

The future of biopharma starts with the people we empower today. Join industry leaders and emerging professionals for an inspiring conversation on what it takes to grow, lead, and thrive in a rapidly evolving industry. From mentorship and career development to building confidence, creating opportunities, and embracing innovation, this session explores how we can bridge generations, unlock potential, and empower the next generation to shape the future of biotech and pharma.

FEATURED SPEAKERS



Demi Lin, MBA

Founder, Demi Elite
Career Advancement Coach
Former Global VP of Strategy, Marketing, BD & Customers

Navigating Difficult Conversations at Work: What to Say When You're Blamed, Your Credit Is Stolen & Executives Push Back



Yi Feng, PhD

Executive Director
Lilly Gene Therapy

Earn Trust, Build Influence: Developing Professional Credibility at Work



Yingchao Zhang, PhD

Co-founder & Chief AI Officer
opAlda

FDEs and Black-Collar Workers: Emerging Careers in the AI Era

Moderated by

Sophie & Mia
Pharma Lobby Podcast

October 18, 2026 • 3:00–4:30 PM
The Inn at Villanova University
601 County Line Road, Radnor, PA 19087
www.iba-usa.org

Conference & Registration

CAREER DEVELOPMENT SESSION

SPEAKER & SESSION LEADERSHIP BIOGRAPHIES

OCT 18, 2026 | 3:00–4:30 PM

FEATURED SPEAKERS

Demi Lin

Demi Lin is an executive career coach and former Global Vice President with over 20 years of experience in multinational corporations. She earned her MBA from Duke University's Fuqua School of Business and held leadership positions at Eastman Chemical, PPG Industries, and Axalta Coating Systems. She led a $1.5 billion global industrial coatings strategy and managed executive teams across three continents. In 2025, she founded Demi Elite and co-founded ASPIRE, a professional community supporting Chinese women overseas. She also shares practical leadership and career advancement insights with over 100,000 social media followers.

Yi Feng

Dr. Yi Feng is Executive Director of Translational Bioanalytical Oversight at Lilly Gene Therapy, with over 20 years of experience across academia, CROs, biotechnology, and pharmaceutical companies. She earned her PhD in Pharmacology from Vanderbilt University and completed postdoctoral research at the University of Pennsylvania. Her expertise spans gene therapy, translational sciences, analytical development, and regulatory strategy. Throughout her career, she has built high-performing teams and external laboratory partnerships supporting preclinical, clinical, and CMC programs. She excels at translating scientific and business needs into practical development strategies and fostering cross-functional collaboration.

FEATURED SPEAKER & MODERATORS

Yingchao Zhang

Dr. Yingchao "YZ" Zhang is a serial entrepreneur, AI innovator, and technology executive with 30 years of experience. As Co-founder and Chief AI Officer of opAIda, he leads AI strategy and innovation in agentic AI and enterprise automation. Beyond his business career, he has served on a local school board and town council. In 2023, he was recognized among the "50 Outstanding Asian Business Leaders." In 2025, New Jersey Governor Phil Murphy appointed him to the Board of Trustees of Thomas Edison State University.

Sophie & Mia

Sophie and Mia are hosts of Pharma Lobby, a Chinese-language podcast exploring careers and professional experiences in the biopharmaceutical industry. Through candid conversations about real-world career challenges, they aim to inspire meaningful reflection and provide practical insights for professionals at different stages of their careers.

INNOVATIVE BIOPHARMACEUTICAL ASSOCIATION

Connect · Collaborate · Advance

IBA 2026 ANNUAL CONFERENCE

Evening Entertainment *Program*

Sunday, October 18, 2026 | 7:00 – 8:20 PM

The Inn at Villanova University

01	**Opening Remarks**	Yi Zhu	
02	**Vocal Performance**	Fancy Shen	*"My Heart Will Go On"*
03	**Vocal Performance**	Jessie Xue	*"Tomorrow" & "Count On Me"*
04	**Chinese Classical Dance**	Priceless Sisters	*"Bu Gua"（卜卦）*
05	**Vocal Ensemble**	Zee A, Pravallika R, Jessica P, Sou M and John L	*"Swing Low, Sweet Chariot"*
06	**Vocal Performance**	Yingchao Zhang	*"What a Wonderful World"*
07	**Vocal Performance**	YingChao Zhang & Fancy Shen	*"Shallow"*
08	**Vocal Performance**	Elaina Wang	*"Mad Hatter" from Alice in Wonderland*
09	**Vocal Trio — Prima 3**	Lihong Meng, Rui Wang, Yun Liu	*"Close to You"*
10	**Dance Performance**	IBA Dance Group	*"La La Land"*
11	**Echo Music Group**	Jingsong, Lian, Chenmei, Nemo, Pu, Wendy, Yaobin, Ying	*"The Sound of Silence"*


Music · Friendship · Celebration




IBA 2026 ANNUAL CONFERENCE

Oct 18, 2026 | The Inn at Villanova University

BALLROOM LAYOUT



MEETING ROOMS



IBA 2026 ANNUAL CONFERENCE

OUR SPONSORS

October 18, 2026 | The Inn at Villanova | Radnor, PA

opAIda LIFE SCIENCES

DIP Deep Intelligent Pharma

FRONTAGE

EDETEK LIFE SCIENCE

WILMINGTON PHARMATECH

NXT POWER®

Tigermed

ICE Innovative CRO+Explorer ICE Bioscience

KPMG

CORIELL INSTITUTE FOR MEDICAL RESEARCH

Tofflon

THANK YOU

iba-usa.org

opAIda

LIFE SCIENCES



AI-POWERED REGULATORY WRITING & QA/QC

FAST. ACCURATE. TRACEABLE.

Automate clinical trial sample analysis QA/QC and regulatory writing — from source data to submission-ready documents — **with experts in control.**

CLINICAL SAMPLE ANALYSIS QA/QC

- PK / ADA / Biomarkers
- Data & Result Verification
- Sample Reconciliation
- Protocol & SOP Compliance

REGULATORY WRITING

- Study Reports (CSR)
- IND / NDA / BLA Support
- CMC
- eCTD

QUALITY & TRACEABILITY

- Automated Consistency Checks
- Evidence Traceability
- Audit Ready
- GxP Aligned (e.g., 21 CFR Part 11)

END-TO-END AI-ASSISTED WORKFLOW

1. SOURCE DATA → 2. AI QA/QC → 3. REGULATORY DRAFT → 4. EXPERT REVIEW → 5. SUBMISSION-READY

LET'S ACCELERATE LIFE-CHANGING THERAPIES.

www.opAIda.ai

Scan to learn more


DIP

Recognized by Over **1000+**
Pharmaceutical Companies Globally
US·Japan·Australia·China·Singapore



The World's #1 LLM- & Agent-Powered Pharmaceutical Clinical CRO

According to **Frost & Sullivan** analysis, in the 2025 global pharmaceutical clinical CRO service market powered by large language models (LLMs) and multi-agent systems, Deep Intelligent Pharma (DIP) ranks first, accounting for approximately 16% market share. DIP launched its LM-related products in 2017 and deployed a multi-agent system framework in 2023, making it one of the earliest companies to operationalize AI-driven clinical R&D services at scale.



Market Position

- DIP
- Competitor A
- Competitor B
- Competitor C
- Others

Data Source: Frost & Sullivan Market Research Report

Key Metrics

2017 Company Established Deeply rooted in the clinical trial services vertical	**400+** Global Employees Covering China, the US, Japan, Australia, and other regions
1000+ Clients Served Pharmaceutical companies, biotechs, hospitals, research institutes, and universities	**50+** Full-Service Projects Ongoing end-to-end clinical projects
40000+ Project Deliveries Cumulative completed clinical trial-related projects	**0** Major Finding Number of major findings in annual audits

Contact Us:
Kevin.he@dip-x.ai
dipgroup.com



FRONTAGE

ONE STOP SHOP FROM DISCOVERY TO COMMERCIAL

Frontage Laboratories, Inc. is a global contract research organization that provides integrated science-driven drug discovery and development services to pharmaceutical and biotechnology companies based in North America, Asia and European continents.

25 Years in Business

2200+ Employees

28 Sites Globally

For more information, contact us at:

Email: info@frontagelab.com
Website: www.frontagelab.com

Comprehensive Services

Discovery & DMPK



- Chemistry & Biology
- ADME/Tox Screening
- Metabolite Profiling
- Pharmacology & Pharmacokinetics
- Radiolabeled Mass Balance/QWBA Studies

Safety & Toxicology



- General Toxicology
- Safety Pharmacology
- Genetic Toxicology
- DART & Juvenile Toxicity
- Ocular
- Carcinogenicity

Laboratory Testing



- Bioanalytical
- Genomics
- Central Lab Services
- Biomarkers & Precision Medicine
- Immunogenicity
- Gene & Cell Therapy

Product Development & Manufacturing



- DS & DP Development
- GMP Manufacturing
- CMC Analytical
- Microbiology
- Commercial Stability

Clinical



- Phase 1 and 2a
- ^{14}C Human AME
- FIH SAD/FE/MAD/DDI
- BE/BA
- TQT
- Medical Writing

WILMINGTON
PHARMATECH

Better API Science.
Reliable American Supply.

Comprehensive US Based API Development & Manufacturing

- CGMP Production in U.S. (up to 3000L)
- HPAPI Facility <10 ng/m^3
- Full Analytical Services and GTIs Trace Analysis

www.wilmingtonpharmatech.com



VISIT US AT BOOTH #10



LAB RELIABILITY STARTS WHEN YOU...

PROTECT THE PROCESS

In modern laboratory environments where precision and compliance are non-negotiable, power protection mission-critical.

Protect the process behind every accurate result by ensuring your instruments receive clean, conditioned power that shields sensitive analyzers, automation systems, and data platforms from electrical disturbances.

Engineered with lab managers in mind and built to support operational continuity NXT Power's advanced power protection solutions help eliminate downtime risk, reduce costly disruptions, and keep workflows running smoothly.

The outcome is a more resilient laboratory infrastructure that protects test accuracy, sustains productivity, and ensures uninterrupted scientific and diagnostic performance.

INDUTRY LEADING TECHNOLOGY

Protect your lab's critical instruments and systems with clean, reliable, and advanced power.

VAST KNOWLEDGE BASE

A dedicated team with deep, hands-on experience in laboratory environment for over 40 years.

UNITERUPTED UPTIME

Minimize costly downtime with power protection engineered to keep laboratory systems running continuously.

Connect with one of our experts and let's start a conversation about strengthening your lab's power reliability and eliminating downtime risk.

NXT POWER®

DELIVERING ULTIMATE POWER PROTECTION
www.nxtpower.com

Tigermed

A Leading Global CRO for Biopharmaceutical Development

We partner with biopharmaceutical companies to turn scientific innovation into therapies that reach patients.

www.tigermedgrp.com
info@tigermedgrp.com



11,900+ Employees Worldwide

4,200+ Customers Worldwide

180+ Locations Worldwide

73+ China Innovative Drugs Supported

Across Asia Pacific, Europe, North America, Latin America and Africa

End-to-End R&D Solutions

From Preclinical Development to Clinical Trials and Commercialization

- Preclinical Development
- Clinical Development
- Regulatory & Integrated Services
- Real-World Evidence
- Commercialization Support


Dedicated to Saving Lives

Innovative CRO Explorer
ICE Bioscience

Mechanism-Driven
RIPTAC
Discovery Services

Transforming Possibilities in Oncology.

TERNARY COMPLEX FORMATION



Target Protein (TP)
Tumor-Enriched

Effector Protein (EP)
Pan-Essential

Induced Proximity.
Selective Killing.

Target & Biology Validation

- TP expression profiling
- Biomarker strategy
- Cell Viability & Resistance
- Mechanism-of-action studies

In Silico Modeling

- Protein–ligand docking
- Ternary complex pose modeling
- Molecular dynamics simulation
- neoPPI interface & binding energy

Ternary Complex & Engagement Assays

- Binary Binding
- Ternary ELISA / TR-FRET
- SPR / Spectral Shift
- NanoBRET target engagement

DMPK & Safety & Efficacy

- ADME & In Vivo PK
- Functional 44 & 77 Safety Panels
- CDX Models
- Biomarker analysis

ICE BIOSCIENCE

Coriell Institute
FOR MEDICAL RESEARCH

Since our inception, Coriell has been providing scientists with high-quality biospecimens to enable biomedical research and for use as gold-standard reference materials. We offer sophisticated laboratory, biobanking, and research core services, along with expert staff able to tailor offerings to meet your needs.

Trusted steward of world-renowned sample collections for the National Institutes of Health, disease foundations, and commercial clients



Biobanking Services
- Clinical trial support
- Collection kits
- Sample management
- Safe storage
- Global distribution
- Project management

Laboratory Services
- Cell culture
- Cytogenetics
- iPSCs
- Molecular biology
- DNA and cell reference materials
- Customized plates and panels
- Quality control, homogeneity, and stability testing

Research Services and Core Facilities
- Cell imaging
- Cell sorting
- Flow cytometry
- Organoids
- Genomic and epigenomic assays
- Bioinformatics

Tofflon

PFS Filling
- High Flexibility
- Compact & Efficient
- Automated & Aseptic
- Configurable



Freeze Dryers
8,000+ Freeze Dryer Installations Since 1993
- Complete end-to-end lyophilization line
- Flexible or fixed automatic loading and unloading systems
- High-performance liquid nitrogen refrigeration



QUALITY ASSURANCE
Compliance with global standards

PROCESS INTEGRATION
Seamless line compatibility

HIGHER PRODUCTIVITY
Optimized performance and reduced downtime

GLOBAL SUPPORT
Local service, worldwide

955 S. Springfield Ave, #107, 1st floor, Building A, Springfield NJ 07081, USA
info.us@tofflon.com